The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

Condition:   Healthy Volunteers Interventions:   Biological: CMAB007;   Biological: Xoliar Sponsor:   Taizhou Mabtech Pharmaceutical Co.,Ltd Completed

Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials